BR112021020601A2 - Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase - Google Patents

Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase

Info

Publication number
BR112021020601A2
BR112021020601A2 BR112021020601A BR112021020601A BR112021020601A2 BR 112021020601 A2 BR112021020601 A2 BR 112021020601A2 BR 112021020601 A BR112021020601 A BR 112021020601A BR 112021020601 A BR112021020601 A BR 112021020601A BR 112021020601 A2 BR112021020601 A2 BR 112021020601A2
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
kinase inhibitor
egfr mutations
compounds containing
cancer compounds
Prior art date
Application number
BR112021020601A
Other languages
English (en)
Inventor
Jacqulyne Robichaux
V Heymach John
Monique Nilsson
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112021020601A2 publication Critical patent/BR112021020601A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase. a presente invenção refere-se a métodos para tratar o câncer em um paciente que foi determinado como tendo mutações do egfr resistentes ao osimertinibe administrando um inibidor de tirosina quinase de terceira geração, como o poziotinibe.
BR112021020601A 2019-04-17 2020-04-16 Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase BR112021020601A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835343P 2019-04-17 2019-04-17
PCT/US2020/028540 WO2020214824A1 (en) 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Publications (1)

Publication Number Publication Date
BR112021020601A2 true BR112021020601A2 (pt) 2021-12-07

Family

ID=72837936

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020601A BR112021020601A2 (pt) 2019-04-17 2020-04-16 Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase

Country Status (12)

Country Link
US (1) US20220175779A1 (pt)
EP (1) EP3956035A4 (pt)
JP (1) JP2022529945A (pt)
KR (1) KR20220004089A (pt)
CN (1) CN113993592A (pt)
AU (1) AU2020257395A1 (pt)
BR (1) BR112021020601A2 (pt)
CA (1) CA3132819A1 (pt)
IL (1) IL287115A (pt)
MX (1) MX2021012705A (pt)
SG (1) SG11202111120VA (pt)
WO (1) WO2020214824A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of FLT3
CN115998743B (zh) * 2023-01-16 2024-05-28 威尚（上海）生物医药有限公司 喹唑啉类化合物在克服奥希替尼耐药中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190125751A1 (en) * 2016-05-18 2019-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CU20190051A7 (es) * 2016-11-17 2020-01-03 Univ Texas Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
WO2018213770A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
WO2019191279A2 (en) * 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
TW202019412A (zh) * 2018-06-25 2020-06-01 美商光譜製藥公司 波齊替尼(poziotinib)與細胞毒性劑及／或其他分子靶向劑之組合及其用途
US20210346383A1 (en) * 2018-09-04 2021-11-11 Rain Therapeutics Inc. Compounds, compositions and methods for treating or preventing her-driven cancers
EP3946293A4 (en) * 2019-03-29 2023-05-03 Board of Regents, The University of Texas System COMPOUNDS WITH ANTITUMORIC ACTIVITIES AGAINST CANCER CELLS WITH EGFR OR HER2 EXON 20 INSERTATIONS
BR112021019376A2 (pt) * 2019-03-29 2021-12-07 Univ Texas Compostos com atividade antitumor contra células cancerígenas transportando inserções de éxon 21 de her2

Also Published As

Publication number Publication date
AU2020257395A1 (en) 2021-11-04
EP3956035A4 (en) 2023-01-25
SG11202111120VA (en) 2021-11-29
US20220175779A1 (en) 2022-06-09
JP2022529945A (ja) 2022-06-27
MX2021012705A (es) 2021-11-12
WO2020214824A1 (en) 2020-10-22
KR20220004089A (ko) 2022-01-11
CN113993592A (zh) 2022-01-28
EP3956035A1 (en) 2022-02-23
IL287115A (en) 2021-12-01
CA3132819A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
BR112021020601A2 (pt) Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase
ECSP19043254A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
BR112013000651A2 (pt) combinações de inibidores de cinase para o tratamento de câncer.
BR112014019052A8 (pt) Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
PH12021551276A1 (en) Combination therapy for the treatment of cancer
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
PH12017501130A1 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
BR112021019376A2 (pt) Compostos com atividade antitumor contra células cancerígenas transportando inserções de éxon 21 de her2
MX2017013358A (es) Métodos para tratar el cáncer.
BR112022010278A2 (pt) Terapia combinada que envolve compostos macrocíclicos de diarila

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]